A well-known noncanonical NF-κB inducer, BAFF, is closely associated with SLE pathogenesis, and BAFF inhibitors have been actively explored in SLE therapy [1, 224]. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.